image credit: julos / Freepik

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

February 12, 2024

The fast-track designation from the US regulator recognises that bepirovirsen is the only single agent in phase 3 that has shown the potential to achieve a “functional cure” when combined with standard CHB therapies based on oral nucleoside or nucleotide analogue (NA) drugs, according to GSK.

Hepatitis B affects almost 300 million people worldwide, according to GSK, and while NAs to treat it are available – such as Gilead’s polymerase inhibitor Viread (tenofovir) – there is still no curative treatment.

Read More on Pharmaphorum